Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...

Raymond James and Cantor both released bullish notes on uniQure (QURE) Tuesday following an update on the company's ...

UniQure (QURE) stock shot up 90% on news the company had reached an agreement with the FDA on an accelerated approval pathway ...

Qure (NASDAQ:QURE – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued to investors on Wednesday. Other research analysts have also ...

Walleye Capital LLC purchased a new stake in uniQure (NASDAQ:QURE – Free Report) in the third quarter, according to the ...

Shares of uniQure (QURE) have gained 5.2% over the past four weeks to close the last trading session at $6.02, but there could still be a solid upside left in the stock if short-term price targets ...

U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License ...

Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and ...

uniQure (QURE) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Read Our Latest Analysis on uniQure uniQure Stock Down 10.1 % Shares of NASDAQ:QURE opened at $6.41 on Wednesday. The stock has a market cap of $312.42 million, a P/E ratio of -1.29 and a beta of ...

uniQure (QURE) announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy, MTLE. “The ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter uniQure ( (QURE)) has shared an update. uniQure N.V. has commenced the dosing of the first patient in its ...